Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cvs health corp. - CVS

CVS

Close Chg Chg %
67.58 -0.45 -0.66%

Closed Market

67.14

-0.45 (0.66%)

Volume: 6.58M

Last Updated:

Mar 28, 2025, 3:59 PM EDT

Trade Now

Company Overview: cvs health corp. - CVS

CVS Key Data

Open

$67.66

 Day Range

66.52 - 67.90

52 Week Range

43.56 - 79.92

 Market Cap

$85.22B

Shares Outstanding

1.26B

 Public Float

1.26B

Beta

0.53

 Rev. Per Employee

N/A

P/E Ratio

18.38

 EPS

$3.67

Yield

395.83%

 Dividend

$0.67

EX-DIVIDEND DATE

Apr 22, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

8.40M

  

CVS Performance

1 Week
 
 0.13%
 
1 Month
 
 2.16%
 
3 Months
 
 50.91%
 
1 Year
 
 -15.82%
 
5 Years
 
 14.57%
 

CVS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 30
Full Ratings ➔

About cvs health corp. - CVS

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS At a Glance

CVS Health Corp.
1 CVS Drive
Woonsocket, Rhode Island 02895
Phone 1-401-765-1500 Revenue 372.69B
Industry Drugstore Chains Net Income 4.61B
Sector Retail Trade 2024 Sales Growth 4.025%
Fiscal Year-end 12 / 2025 Employees 300,000
View SEC Filings

CVS Valuation

P/E Current 18.38
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 12.278
Price to Sales Ratio 0.152
Price to Book Ratio 0.749
Price to Cash Flow Ratio 6.221
Enterprise Value to EBITDA 8.862
Enterprise Value to Sales 0.345
Total Debt to Enterprise Value 0.645

CVS Efficiency

Revenue/Employee 1,242,306.667
Income Per Employee 15,380.00
Receivables Turnover 10.219
Total Asset Turnover 1.437

CVS Liquidity

Current Ratio 0.811
Quick Ratio 0.597
Cash Ratio 0.131

CVS Profitability

Gross Margin 13.76
Operating Margin 2.662
Pretax Margin 1.65
Net Margin 1.238
Return on Assets 1.78
Return on Equity 6.07
Return on Total Capital 2.911
Return on Invested Capital 3.054

CVS Capital Structure

Total Debt to Total Equity 109.741
Total Debt to Total Capital 52.322
Total Debt to Total Assets 31.792
Long-Term Debt to Equity 99.823
Long-Term Debt to Total Capital 47.593
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cvs Health Corp. - CVS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
291.94B 322.79B 358.27B 372.69B
Sales Growth
+8.67% +10.57% +10.99% +4.02%
Cost of Goods Sold (COGS) incl D&A
240.06B 268.17B 303.35B 321.41B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.51B 4.25B 4.37B 4.60B
Depreciation
2.25B 2.44B 2.46B 2.57B
Amortization of Intangibles
2.26B 1.81B 1.91B 2.02B
COGS Growth
+9.29% +11.71% +13.12% +5.95%
Gross Income
51.87B 54.61B 54.93B 51.28B
Gross Income Growth
+5.87% +5.29% +0.57% -6.63%
Gross Profit Margin
+17.77% +16.92% +15.33% +13.76%
2021 2022 2023 2024 5-year trend
SG&A Expense
36.93B 38.21B 39.34B 41.36B
Research & Development
- - - -
-
Other SG&A
36.93B 38.21B 39.34B 41.36B
SGA Growth
+5.31% +3.46% +2.97% +5.13%
Other Operating Expense
- - - -
-
Unusual Expense
2.37B 5.80B 994.00M 1.03B
EBIT after Unusual Expense
12.56B 10.60B 14.59B 8.89B
Non Operating Income/Expense
324.00M (2.70B) (777.00M) 196.00M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.47B 2.27B 2.64B 2.94B
Interest Expense Growth
-14.03% -7.98% +16.15% +11.33%
Gross Interest Expense
2.47B 2.27B 2.64B 2.94B
Interest Capitalized
- - - -
-
Pretax Income
10.42B 5.63B 11.17B 6.15B
Pretax Income Growth
+6.65% -45.99% +98.53% -44.97%
Pretax Margin
+3.57% +1.74% +3.12% +1.65%
Income Tax
2.52B 1.46B 2.81B 1.56B
Income Tax - Current - Domestic
2.95B 3.54B 3.48B 2.13B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(428.00M) (2.08B) (676.00M) (572.00M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
7.90B 4.17B 8.37B 4.59B
Minority Interest Expense
(12.00M) 16.00M 24.00M (28.00M)
Net Income
7.91B 4.15B 8.34B 4.61B
Net Income Growth
+10.04% -47.55% +101.11% -44.70%
Net Margin Growth
+2.71% +1.29% +2.33% +1.24%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
7.91B 4.15B 8.34B 4.61B
Preferred Dividends
- - - -
-
Net Income Available to Common
7.91B 4.15B 8.34B 4.61B
EPS (Basic)
5.997 3.1624 6.4934 3.6648
EPS (Basic) Growth
+9.35% -47.27% +105.33% -43.56%
Basic Shares Outstanding
1.32B 1.31B 1.28B 1.26B
EPS (Diluted)
5.9518 3.136 6.4682 3.6561
EPS (Diluted) Growth
+8.94% -47.31% +106.26% -43.48%
Diluted Shares Outstanding
1.33B 1.32B 1.29B 1.26B
EBITDA
19.45B 20.65B 19.95B 14.52B
EBITDA Growth
+5.92% +6.16% -3.39% -27.22%
EBITDA Margin
+6.66% +6.40% +5.57% +3.90%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 72.261
Number of Ratings 30 Current Quarters Estimate 1.653
FY Report Date 03 / 2025 Current Year's Estimate 5.90
Last Quarter’s Earnings 1.19 Median PE on CY Estimate N/A
Year Ago Earnings 5.42 Next Fiscal Year Estimate 6.873
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 22 22 26 22
Mean Estimate 1.65 1.58 5.90 6.87
High Estimates 1.96 1.74 6.50 7.59
Low Estimate 0.97 1.29 5.63 6.26
Coefficient of Variance 12.10 7.34 2.68 5.01

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 16
OVERWEIGHT 3 3 3
HOLD 11 10 10
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Cvs Health Corp. - CVS

Date Name Shares Transaction Value
Mar 17, 2025 Anne M. Finucane Director 28,964 Bona fide gift Non-derivative transaction at $97.35 per share 2,819,645.40
Feb 27, 2025 Michael F. Mahoney Director 39,356 Open market or private purchase of non-derivative security Non-derivative transaction at $66.7 per share 2,625,045.20
Nov 26, 2024 Anne M. Finucane Director 12,173 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2024 Fernando G. Aguirre Director 36,887 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 2,106,247.70
Nov 26, 2024 Mary Lovelace Schapiro Director 24,437 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2024 Nancy-Ann M. DeParle Director 34,169 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 1,951,049.90
Nov 26, 2024 C. David Brown Director 123,765 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 7,066,981.50
Nov 26, 2024 Lawrence Michael Robbins Director 2,933 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2024 Guy P. Sansone Director 8,360 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 477,356.00
Nov 26, 2024 J. Scott Kirby Director 8,566 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 489,118.60
Nov 26, 2024 Leslie V. Norwalk Director 2,200 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 125,620.00
Nov 26, 2024 Jean-Pierre Millon Director 4,514 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 257,749.40
Nov 26, 2024 Douglas H. Shulman Director 2,200 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 125,620.00
Nov 26, 2024 Alecia A. DeCoudreaux Director 34,934 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2024 Jeffrey R. Balser Director 9,652 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.1 per share 551,129.20
May 3, 2024 Edward J. Ludwig Director 21,630 Open market or private purchase of non-derivative security Non-derivative transaction at $53.88 per share 1,165,424.40

Cvs Health Corp. in the News

Why neighborhood pharmacies are closing

Retail pharmacies will never be obsolete, according to an analyst. But the industry needs to take a hard look at how many stores are needed and what items they should sell.

CVS Health to cut 2,900 jobs

CVS Health is slashing its headcount by 2,900, or 1% of its total workforce. The layoffs will largely focus on corporate positions, a spokesperson said.

CVS cuts outlook, plans $2B cost-cutting effort

CVS said Wednesday that it's launching a multi-year productivity initiative. It also cut its outlook for the year as its health care benefits segment continues to face pressure.